Sex chromosome changes in leukemia: cytogenetics and molecular aspects

References

• Tang Z, Medeiros LJ, Yin CC, et al. Sex chromosome loss after allogeneic hematopoietic stem cell transplant in patients with hematologic neoplasms: a diagnostic dilemma for clinical cytogeneticists. Mol Cytogenet. 2016;9(1):141.
   Google Scholar
• Lippert E, Etienne G, Mozziconacci M-J, et al. Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinibmesylate therapy. Haematologica. 2010;95(9):1604–1607. doi: 10.3324/haematol.2009.019109
   PubMed Web of Science ®Google Scholar
• Chapiro E, Antony-Debre I, Marchay N, et al. Sex chromosome loss may represent a disease-associated clonal population in chronic lymphocytic leukemia. Genes Chromosome Canc. 2014;53(3):240–247. doi: 10.1002/gcc.22134
   PubMed Web of Science ®Google Scholar
• Gupta A, Parihar M, Remani AS, et al. Loss of chromosome Y in acute lymphoblastic leukemia: age related or neoplastic phenomenon? Indian J Pathol Microbiol. 2014;57(3):431. doi: 10.4103/0377-4929.138742
   PubMed Web of Science ®Google Scholar
• Wong AK, Fang B, Zhang L, et al. Loss of the Y chromosome: an age-related or clonal phenomenon in acute myelogenous leukemia/myelodysplastic syndrome? Arch Pathol Lab Med. 2008;132(8):1329–1332.
   PubMed Web of Science ®Google Scholar
• Minner S, Kilgué A, Stahl P, et al. Y chromosome loss is a frequent early event in urothelial bladder cancer. Pathology. 2010;42(4):356–359. doi: 10.3109/00313021003767298
   PubMed Web of Science ®Google Scholar
• Andreieva S, Korets K, Kyselova O, et al. Chronic myeloid leukemia in a patient with the Klinefelter syndrome. Exp Oncol. 2016;38(3):195–197.
   PubMedGoogle Scholar
• Zhang LJ, Shin ES, Yu ZX, et al. Molecular genetic evidence of Y chromosome loss in male patients with hematological disorders. Chin Med J. 2007;120(22):2002–2005.
   PubMed Web of Science ®Google Scholar
• Michaux L, Wlodarska I, Mecucci C, et al. Characterization by chromosome painting of balanced and unbalanced X chromosome translocations in myelodysplastic syndromes. Cancer Genet Cytogenet. 1995;82(1):17–22. doi: 10.1016/0165-4608(94)00283-H
   PubMedGoogle Scholar
• Wolff D, Knopp A, Weirich V, et al. Loss of the GVL effect by loss of the Y-chromosome as putative mechanism of immune escape in ALL. Bone Marrow Transplant. 2005;35(1):101–102. doi: 10.1038/sj.bmt.1704712
   PubMed Web of Science ®Google Scholar
• Ganster C, Kämpfe D, Jung K, et al. New data shed light on Y-loss-related pathogenesis in myelodysplastic syndromes. Genes Chromosome Canc. 2015;54(12):717–724. doi: 10.1002/gcc.22282
   PubMed Web of Science ®Google Scholar
• Olshanskaya YV, Udovichenko AI, Vodinskaya LA, et al. Myelodysplastic syndromes with isolated deletion of the long arm of the chromosome X as a sole cytogenetic change. Cancer Genet Cytogenet. 2006;167(1):47–50. doi: 10.1016/j.cancergencyto.2005.08.018
   PubMedGoogle Scholar
• Shon W, Peters MS, Reed KB, et al. Atypical generalized eruptive histiocytosis clonally related to chronic myelomonocytic leukemia with loss of Y chromosome. J Cutan Pathol. 2013;40(8):725–729. doi: 10.1111/cup.12168
   PubMed Web of Science ®Google Scholar
• Rowley JD. Recurring chromosome abnormalities in leukemia. Semin Hematol. 1990;27:122–136.
   PubMed Web of Science ®Google Scholar
• Mohamed M, Dun K. Acute myeloid leukaemia with t(8; 21)(q22; q22. 3) and loss of the X chromosome. BMJ Case Reports. 2015.
   Google Scholar
• Kumari P, LingappaKavitha B, Reddy CO, et al. A rare cytogenetic presentation of acute myeloid leukemia (AML-M2). Acta Med Iran. 2012;50(12):827.
   PubMedGoogle Scholar
• Kuchenbauer F, Schnittger S, Look T, et al. Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t (8; 21)/AML1-ETO. Br J Haematol. 2006;134(6):616–619. doi: 10.1111/j.1365-2141.2006.06229.x
   PubMed Web of Science ®Google Scholar
• Wu Y, Xue Y, Pan J. Y-chromosome loss in acute promyelocytic leukemia. Cancer Genet Cytogenet. 2005;157(1):90–91. doi: 10.1016/j.cancergencyto.2004.04.022
   PubMedGoogle Scholar
• Othman MA, Vujić D, Zecević Z, et al. A cryptic three-way translocation t (10; 19; 11)(p12. 31; q13. 31; q23. 3) with a derivative Y-chromosome in an infant with acute myeloblastic leukemia (M5b). Gene. 2015;563:115–119. doi: 10.1016/j.gene.2015.02.064
   PubMed Web of Science ®Google Scholar
• Wiktor A, Rybicki BA, Piao ZS, et al. Clinical significance of Y chromosome loss in hematologic disease. Genes Chromosome Canc. 2000;27(1):11–16. doi: 10.1002/(SICI)1098-2264(200001)27:1<11::AID-GCC2>3.0.CO;2-I
   PubMed Web of Science ®Google Scholar
• Abeliovich D, Yehuda O, Ben-Neriah S, et al. Loss of Y chromosome. An age-related event or a cytogenetic marker of a malignant clone? Cancer Genet Cytogenet. 1994;76:70–71. doi: 10.1016/0165-4608(94)90075-2
   PubMedGoogle Scholar
• Settin A, Al Haggar M, Al Dosok T, et al. Prognostic cytogenetic markers in childhood acute lymphoblastic leukemia: cases from Mansoura, Egypt. Hematology. 2006;11(5–6):341–349. doi: 10.1080/10245330600938174
   PubMed Web of Science ®Google Scholar
• Heerema NA, Harbott J, Galimberti S, et al. Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia. 2004;18:693–702. doi: 10.1038/sj.leu.2403324
   PubMed Web of Science ®Google Scholar
• Vijayakumar S, Garcia D, Hensel CH, et al. The human Y chromosome suppresses the tumorigenicity of PC-3, a human prostate cancer cell line, in athymic nude mice. Genes Chromosome Canc. 2005;44:365–372. doi: 10.1002/gcc.20250
   PubMed Web of Science ®Google Scholar
• Russell LJ, Capasso M, Vater I, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood. 2009;114:2688–2698. doi: 10.1182/blood-2009-03-208397
   PubMed Web of Science ®Google Scholar
• Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in “good-risk" chronic granulocytic leukemia. Blood. 1984;63(4):789–799.
   PubMed Web of Science ®Google Scholar
• Wang W, Cortes JE, Tang G, et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016;127(22):2742–2750. doi: 10.1182/blood-2016-01-690230
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European leukemianet recommendations for the management of chronic myeloid leukemia. Blood. 2013;122(6):872–884. doi: 10.1182/blood-2013-05-501569
   PubMed Web of Science ®Google Scholar
• Perrotti D, Jamieson C, Goldman J, et al. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010;120(7):2254–2264. doi: 10.1172/JCI41246
   PubMed Web of Science ®Google Scholar
• Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7(6):441–453. doi: 10.1038/nrc2147
   PubMed Web of Science ®Google Scholar
• Luatti S, Castagnetti F, Marzocchi G, et al. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA working party on CML analysis. Blood. 2012;120(4):761–767. doi: 10.1182/blood-2011-10-384651
   PubMed Web of Science ®Google Scholar
• Wang W, Cortes JE, Lin P, et al. Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. Leukemia. 2015;29(11):2263–2266. doi: 10.1038/leu.2015.96
   PubMed Web of Science ®Google Scholar
• Mallo M, Luño E, Sanzo C, et al. Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome. Leuk Res. 2011;35(6):834–836. doi: 10.1016/j.leukres.2011.01.003
   PubMed Web of Science ®Google Scholar
• Cogle CR, Saki N, Khodadi E, et al. Bone marrow niche in the myelodysplastic syndromes. Leuk Res. 2015;39(10):1020–1027. doi: 10.1016/j.leukres.2015.06.017
   PubMed Web of Science ®Google Scholar
• Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110:4385–4395. doi: 10.1182/blood-2007-03-082404
   PubMed Web of Science ®Google Scholar
• Boultwood J, Wainscoat JS. Clonality in the myelodysplastic syndromes. Int J Hematol. 2001;73:411–415. doi: 10.1007/BF02994002
   PubMed Web of Science ®Google Scholar
• Wiktor AE, Van Dyke DL, Hodnefield JM, et al. The significance of isolated Y chromosome loss in bone marrow metaphase cells from males over age 50 years. Leuk Res. 2011;35:1297–1300. doi: 10.1016/j.leukres.2011.05.002
   PubMed Web of Science ®Google Scholar
• Vehmeyer K, Haase D, Alves F. Increased peripheral stem cell pool in MDS: an indication of disease progression? Leuk Res. 2001;25:955–959. doi: 10.1016/S0145-2126(01)00064-9
   PubMed Web of Science ®Google Scholar
• Braulke F, Jung K, Schanz J. Molecular cytogenetic monitoring from CD341 peripheral blood cells in myelodysplastic syndromes – first results from a prospective multicenter German diagnostic study. Leuk Res. 2013;37:900–906. doi: 10.1016/j.leukres.2013.03.019
   PubMed Web of Science ®Google Scholar
• Forsberg LA, Rasi C, Malmqvist N, et al. Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. Nat Genet. 2014;46:624–628. doi: 10.1038/ng.2966
   PubMed Web of Science ®Google Scholar
• Knight JC, Grimaldi G, Thiesen H-J, et al. Clustered organization of Krfippel zinc-finger genes at Xp11.23, flanking a translocation breakpoint at OATLI: a physical map with locus assignment for ZNF21, ZNF41, ZNF81, and ELK1. Genomics. 1994;21:180–187. doi: 10.1006/geno.1994.1240
   PubMed Web of Science ®Google Scholar
• de Leeuw B, Suikerbuijk RF, OldeWeghuis D, et al. Distinct Xp11.2 breakpoint regions in synovial sarcoma revealed by metaphase and interphase FISH: relationship to histologic subtypes. Cancer Genet Cytogenet. 1994;73:89–94. doi: 10.1016/0165-4608(94)90191-0
   PubMed Web of Science ®Google Scholar
• Nielander I, Martin-Subero JI, Wagner F, et al. Recurrent loss of the Y chromosome and homozygous deletions within the pseudoautosomal region 1: association with male predominance in mantle cell lymphoma. Haematologica. 2008;93:949–950. doi: 10.3324/haematol.12656
   PubMed Web of Science ®Google Scholar
• Weng S, Stoner S, Zhang D. Sex chromosome loss and the pseudoautosomal region genes in hematological malignancies. Oncotarget. 2016;7(44):72356–72372. doi: 10.18632/oncotarget.12050
   PubMed Web of Science ®Google Scholar
• Testa U, Riccioni R, Diverio D, et al. Interleukin-3 receptor in acute leukemia. Leukemia. 2004;18(2):219–226. doi: 10.1038/sj.leu.2403224
   PubMed Web of Science ®Google Scholar
• Hruz T, Laule O, Szabo G, et al. Genevestigator v3: a reference expression database for the meta-analysis of transcriptomes. Adv Bioinform. 2008;2008:1–5. doi: 10.1155/2008/420747
   Google Scholar
• Hornakova T, Staerk J, Royer Y, et al. Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers. J Biol Chem. 2009;284(11):6773–6781. doi: 10.1074/jbc.M807531200
   PubMed Web of Science ®Google Scholar
• Rochman Y, Kashyap M, Robinson GW, et al. Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling. Proc Natl Acad Sci USA. 2010;107(45):19455–19460. doi: 10.1073/pnas.1008271107
   PubMed Web of Science ®Google Scholar
• Dworzak MN, Fröschl G, Printz D, et al. CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease. Leukemia. 2004;18(4):703–708. doi: 10.1038/sj.leu.2403303
   PubMed Web of Science ®Google Scholar
• Büyükavci M, Ozdemir O, Buck S, et al. Melatonin cytotoxicity in human leukemia cells: relation with its pro-oxidant effect. Fundam Clin Pharmacol. 2006;20(1):73–79. doi: 10.1111/j.1472-8206.2005.00389.x
   PubMed Web of Science ®Google Scholar
• Zhang J, Mullighan CG, Harvey RC, et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the children’s oncology group. Blood. 2011;118(11):3080–3087. doi: 10.1182/blood-2011-03-341412
   PubMed Web of Science ®Google Scholar
• Mumby M. PP2A: unveiling a reluctant tumor suppressor. Cell. 2007;130(1):21–24. doi: 10.1016/j.cell.2007.06.034
   PubMed Web of Science ®Google Scholar
• Yang Z, Cheng W, Hong L, et al. Adenine nucleotide (ADP/ATP) translocase 3 participates in the tumor necrosis factor induced apoptosis of MCF-7 cells. Mol Biol Cell. 2007;18(11):4681–4689. doi: 10.1091/mbc.E06-12-1161
   PubMed Web of Science ®Google Scholar
• Nieländer I, Martín-Subero JI, Wagner F, et al. Recurrent loss of the Y chromosome and homozygous deletions within the pseudoautosomal region 1: association with male predominance in mantle cell lymphoma. Haematologica. 2008;93(6):949–950. doi: 10.3324/haematol.12656
   PubMed Web of Science ®Google Scholar
• United Kingdom Cancer Cytogenetics Group (UKCCG). Loss of the Y chromosome from normal and neoplastic and bone marrows. Genes Chromosome Canc. 1992;5:83–88. doi: 10.1002/gcc.2870050112
   PubMed Web of Science ®Google Scholar
• Riske CB, Morgan R, Ondreyco S, et al. X and Y chromosome loss as sole abnormality in acute non-lymphocytic leukemia (ANLL). Cancer Genet Cytogenet. 1994;72:44–47. doi: 10.1016/0165-4608(94)90108-2
   PubMed Web of Science ®Google Scholar
• Herens C, Brasseur E, Jamar M, et al. Loss of the Y chromosome in bone marrow cells: results on 1907 consecutive cases of leukemia and proleukemia. Clin Lab Haem. 1999;21:17–20. doi: 10.1046/j.1365-2257.1999.00173.x
   PubMedGoogle Scholar
• Randolph SS, Gooley TA, Warren EH, et al. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood. 2004;103:347–352. doi: 10.1182/blood-2003-07-2603
   PubMed Web of Science ®Google Scholar
• Aly MS, Khaled HM. Chromosomal aberrations in early-stage bilharzial bladder cancer. Cancer Genet Cytogenet. 2002;132:41–45. doi: 10.1016/S0165-4608(01)00527-1
   PubMedGoogle Scholar
• Toubai T, Tanaka J, Ota S, et al. Allogeneic bone marrow transplantation from an unrelated donor for the treatment of chronic myelogenous leukemia in blast crisis in a patient with Klinefelter’s syndrome. Leuk Lymphoma. 2004;45:829–831. doi: 10.1080/10428190310001607188
   PubMed Web of Science ®Google Scholar
• Chennuri V, Kashyap R, Tamhankar P, et al. Chronic myeloid leukemia in case of Klinefeltersyndrome. Indian J Hum Genet. 2014;20:69–71. doi: 10.4103/0971-6866.132760
   PubMedGoogle Scholar
• Chakraborty R, Mukkamalla SKR, Singam K, et al. Persistent suboptimal molecular response in a patient with chronic myelogenous leukemia and Klinefelter syndrome. Korean J Intern Med. 2014;29:827–829. doi: 10.3904/kjim.2014.29.6.827
   PubMed Web of Science ®Google Scholar